Superworth

Agilent Technologies PE ratio A

Share price divided by earnings per share over the last twelve months, since 2010.

Today, Oct 23, 2026
34.0×
10-year median
33.1×
Against its 10-year history
58th
percentile: 0 is its lowest day, 100 its highest
10-year range
19.3× to 121×
Peer median
39.3×

Agilent Technologies' PE ratio is 34.0× as of Oct 23, 2026: a share price of $173.07 against $5.09 of earnings per share over the last twelve months.

That is above its ten-year median of 33.1×, close to the middle of its last ten years.

Over that time it ranged from 19.3× in May 2019 to 121× in Mar 2018.

The median for 10 diagnostics and research stocks of a similar size is 39.3×.

PE ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far34.0×24.3×34.0×
202530.2×23.5×35.9×
202430.6×26.5×36.9×
202333.2×25.4×37.5×
202235.8×27.2×36.9×
202140.6×40.2×58.3×
202051.5×22.9×53.6×
201925.4×19.3×82.9×
201867.3×31.9×121×
201731.9×31.9×39.0×
201632.3×28.8×34.6×
201534.8×25.3×50.0×
201427.8×17.3×27.8×
201319.4×9.2×19.4×
20128.7×8.5×11.4×
20118.8×7.9×17.3×
201015.4×15.2×44.7×

Against its peers

Companies in Medical - Diagnostics & Research nearest Agilent Technologies' size, closest first, today.

CompanyPE ratio
AAgilent Technologies34.0×
IQVIQVIA34.7×
WATWaters113×
IDXXIDEXX Laboratories39.4×
ILMNIllumina50.1×
MTDMettler-Toledo International37.6×
DGXQuest Diagnostics25.7×
LHLabcorp27.2×
MEDPMedpace39.2×
RVTYRevvity75.6×
DHRDanaher40.9×
Peer median39.3×

Where Agilent Technologies ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Agilent Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.